Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
British Columbia Cancer Agency
With
BC Cancer Foundation
Men with intermediate or high risk prostate cancer who are technically suitable for prostate brachytherapy based on prostate size and voiding function and who are interested in this modality of treatment will be approached for randomization between either high dose rate (single 15 Gray) or low dose rate permanent seed implant (110 Gray) brachytherapy. Baseline International Prostate Symptom score, Quality of Life Assessment and International Index of Erectile Function will be recorded and then every 3 months for the first year and every 6 months to 3 years. Androgen deprivation treatment is allowed for 6 or 12 months.
Age
45–80
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Upper tier intermediate risk with at least 2 of the following factors
1. Tumor-Nodes-Metastases Tumor stage T2B or greater
2. Gleason Score 7
3. PSA \> 10
4. \> 50% of the biopsies positive
OR High risk prostate cancer with one of the following factors
1. T3a
2. Gleason Score8-10
3. PSA \>20
Positive prostate biopsy within 12 months (reviewed centrally)
International Prostate Symptom Score \< 16
Prostate volume \< 60 cc
Negative staging CT and Bone scan within 3 months prior to registration
History and physical examination within 90 days prior to registration
European Cooperative Oncology Group performance status 0-1 prior to registration
Age \>45
Patient suitable for procedure under anesthesia
You may not be if
Prior invasive malignancy (except non melanoma skin cancer) unless disease-free for at least 3 years prior to registration
Previous prostatectomy, cryotherapy or High Intensity Focussed Ultrasound for prostate cancer
Previous pelvic irradiation or prostate brachytherapy
Clareo Health | Improving Quality of Life After Prostate Brachytherapy: a Comparison of HDR and LDR Brachytherapy
